Kronos Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.74 M
- Company Age 12 Year, 3 Months
- Last Filing with ROC 31 Mar 2018
- Open Charges ₹ 0.90 M
About Kronos Pharmaceutical
Kronos Pharmaceutical Private Limited (KPPL) is a Private Limited Indian Non-Government Company incorporated in India on 25 October 2012 and has a history of 12 years and three months. Its registered office is in Singhbhum, Jharkhand, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2018. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.74 M.
The company currently has active open charges totaling ₹0.90 M.
Jitendra Srivastava, Pushpa Srivastava, and Vikash Srivastava serve as directors at the Company.
Company Details
- Location
Singhbhum, Jharkhand, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U52310JH2012PTC000761
- Company No.
000761
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
25 Oct 2012
- Date of AGM
29 Oct 2018
- Date of Balance Sheet
31 Mar 2018
- Listing Status
Unlisted
- ROC Code
Roc Jharkhand
Industry
Who are the key members and board of directors at Kronos Pharmaceutical?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jitendra Srivastava  | Director | 25-Oct-2012 | Current |
| Pushpa Srivastava | Director | 25-Oct-2012 | Current |
| Vikash Srivastava | Director | 25-Oct-2012 | Current |
Financial Performance of Kronos Pharmaceutical.
Enhance accessibility to Kronos Pharmaceutical's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Kronos Pharmaceutical?
Unlock access to Kronos Pharmaceutical's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
₹0.90 M
₹0
Charges Breakdown by Lending Institutions
- Bank Of India : 0.09 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 21 Nov 2013 | Bank Of India | ₹0.90 M | Open |
How Many Employees Work at Kronos Pharmaceutical?
Unlock and access historical data on people associated with Kronos Pharmaceutical, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Kronos Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Kronos Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.